Spinal Cord Injury
Neurology·MeSH: Spinal Cord Injuries
Prevalence
30.0 / 100K
5 drugs in development·4 companies·12 clinical trials
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| Elezanumab | AbbVie Inc. (ABBV) |
Phase 1(1)
| Drug | Company |
|---|---|
| opc1 | Lineage Cell Therapeutics, Inc. (LCTX) |
Early Phase 1(2)
Phase 4(1)
Compare drugs
Frequently asked questions
How many drugs are in development for Spinal Cord Injury?
BioSniper tracks 5 drugs in development for Spinal Cord Injury across 4 companies.
How many clinical trials target Spinal Cord Injury?
There are 12 clinical trials targeting Spinal Cord Injury tracked by BioSniper.
What is the prevalence of Spinal Cord Injury?
The estimated prevalence of Spinal Cord Injury is approximately 30.0 per 100,000 population.
Deep-dive into Spinal Cord Injury
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis